Fig. 3From: MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinomaReceiver operating characteristic (ROC) curves for evaluating HCC treatment responses. A, C ROC curves illustrating the discriminative performance of four models—SVM, XGBoost, RF, and LR—in differentiating between the treatment and control groups. (A) uses T1w MRI data, (B) uses T2w MRI data, and (C) uses a combined T1w + T2w MRI dataset. D–F ROC curves showing the classification abilities of the same models across various treatment groups based on (D) T1w MRI, (E) T2w MRI, and (F) combined T1w + T2w MRI datasets. These groups include the control group (no treatment), sorafenib-only treatment, NK cell infusion via hepatic artery (IHA), and a combination therapy of sorafenib and NK cell IHABack to article page